Key facts
- It has raised $97.2M across 2 recorded rounds; the latest was Later Stage VC ($77.0M) in Dec 2020.
- Notable investors include GV, Wellington Management, Polaris Partners, Logos Capital, Sonostar Ventures — 8 tracked in total.
- IconOVir Bio has filed 2 Form Ds with the SEC since 2020, most recently Jun 2024 ($20.2M sold to 34 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for IconOVir Bio
Funding rounds
2 roundsAbout IconOVir Bio
Operator of a preclinical-stage biotechnology company intended to improve the treatment of patients with cancer. The company's proprietary oncolytic virus platform is designed to address key limitations of first- and second-generation oncolytic viruses, enabling healthcare professionals to provide personalized therapy for cancer patients.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2018
- Employees
- 12
- Website
- iconovir.com/
- Ownership
- Privately Held (backing)
IconOVir Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in IconOVir Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on IconOVir Bio in its N-PORT filings yet. We sweep new filings monthly.